Compare NXL & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | VVOS |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 17.4M |
| IPO Year | N/A | 2020 |
| Metric | NXL | VVOS |
|---|---|---|
| Price | $0.51 | $1.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 384.5K | 94.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,031,000.00 |
| Revenue This Year | $38.28 | $28.86 |
| Revenue Next Year | $185.71 | $48.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.91 |
| 52 Week Low | $0.37 | $1.42 |
| 52 Week High | $2.80 | $7.40 |
| Indicator | NXL | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 36.58 |
| Support Level | $0.37 | $1.44 |
| Resistance Level | $0.69 | $1.88 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 51.97 | 6.82 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.